SCHEMBL22324880

SCHEMBL22324880

O=C1CCCN1Cc1ccc(C2CCNCC2)cc1F

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 2/20 0.46
CYP2C9 P11712 2/20 0.46
GRIA2 P42262 1/20 0.46
SLC6A2 P23975 4/20 0.45
SLC6A4 P31645 4/20 0.45
SLC6A3 Q01959 4/20 0.45
BDKRB1 P46663 1/20 0.44
MAPK1 P28482 1/20 0.41
KMT2A Q03164 1/20 0.41
TLR7 Q9NYK1 4/20 0.40
PLAT P00750 1/20 0.39
HRH3 Q9Y5N1 3/20 0.38
RORC P51449 1/20 0.37
ALDH1A1 P00352 2/20 0.37
QDPR P09417 1/20 0.37
KDM4E B2RXH2 1/20 0.36
POLB P06746 1/20 0.36
CYP3A4 P08684 1/20 0.36
CYP2D6 P10635 1/20 0.36
MAPT P10636 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22324823 0.86 ALDH1A1 (0.44) SLC6A2SLC6A4SLC6A3MAPK1KMT2A
SCHEMBL22324961 0.80 GRIA2 (0.42) CYP1A2CYP2C9GRIA2SLC6A2SLC6A4
SCHEMBL22324774 0.80 CYP1A2 (0.42) CYP1A2CYP2C9GRIA2SLC6A2SLC6A4
SCHEMBL22324948 0.80 L3MBTL1 (0.52) CYP1A2CYP2C9GRIA2PLATHRH3
SCHEMBL22324883 0.79 GRIA2 (0.44) CYP1A2CYP2C9GRIA2SLC6A2SLC6A4
SCHEMBL20004077 0.76 KDM4E (0.55) CYP1A2CYP2C9GRIA2BDKRB1MAPK1
SCHEMBL22324855 0.76 L3MBTL1 (0.43) CYP1A2CYP2C9GRIA2SLC6A2SLC6A4
SCHEMBL6109530 0.75 SLC6A2 (0.46) SLC6A2SLC6A4SLC6A3MAPK1KMT2A
SCHEMBL23638961 0.74 CYP1A2 (0.50) CYP1A2CYP2C9GRIA2BDKRB1MAPK1
SCHEMBL1424192 0.74 BDKRB1 (0.50) CYP1A2CYP2C9GRIA2BDKRB1MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12479816-B2 20-HETE formation inhibitors University of Pittsburgh—of the Commonwealth System of Higher Education (US) 2025-11-25 US disclosed
US-20220144797-A1 20-HETE FORMATION INHIBITORS UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2022-05-12 US disclosed
US-20220144797-A1 20-HETE FORMATION INHIBITORS UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2022-05-12 US disclosed
WO-2020163689-A1 20-HETE FORMATION INHIBITORS UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2020-08-13 WO disclosed
WO-2020163689-A1 20-HETE FORMATION INHIBITORS UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2020-08-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220144797-A1 20-HETE FORMATION INHIBITORS CYP4A22, ALOX5, ALOX15 CYP1A2 41/4885CYP2C9 84/4885GRIA2 1400/4885
US-12479816-B2 20-HETE formation inhibitors CYP4A22, ALOX5, ALOX15 CYP1A2 41/4885CYP2C9 84/4885GRIA2 1400/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.